Boston Scientific Corporation (NYSE:BSX) Receives Average Recommendation of “Moderate Buy” from Analysts

Boston Scientific Corporation (NYSE:BSX) has received an average recommendation of “Moderate Buy” from the twenty-five ratings firms that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating, twenty-two have given a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $102.9091.

A number of research firms recently commented on BSX. Oppenheimer decreased their target price on shares of Boston Scientific from $125.00 to $100.00 and set an “outperform” rating for the company in a research report on Friday, January 16th. Barclays decreased their target price on shares of Boston Scientific from $136.00 to $124.00 and set an “overweight” rating for the company in a research report on Tuesday, February 3rd. Jefferies Financial Group reissued a “buy” rating on shares of Boston Scientific in a research report on Monday, March 16th. National Bank Financial set a $115.00 target price on shares of Boston Scientific in a research report on Monday, February 2nd. Finally, Royal Bank Of Canada reissued an “outperform” rating and set a $115.00 target price on shares of Boston Scientific in a research report on Monday, March 30th.

Boston Scientific Trading Up 1.0%

NYSE:BSX opened at $63.82 on Wednesday. Boston Scientific has a one year low of $60.59 and a one year high of $109.50. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62. The firm has a market cap of $94.85 billion, a P/E ratio of 32.90, a P/E/G ratio of 0.98 and a beta of 0.78. The firm has a 50-day simple moving average of $70.34 and a 200-day simple moving average of $87.52.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The business had revenue of $5.29 billion during the quarter, compared to analyst estimates of $5.29 billion. During the same quarter in the previous year, the business posted $0.70 EPS. The company’s quarterly revenue was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Equities analysts anticipate that Boston Scientific will post 2.85 EPS for the current fiscal year.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Citi reiterated a Buy on BSX (while trimming its price target from $98 to $87), keeping analyst backing and signaling conviction that shares have meaningful upside potential. Citi Reiterates Buy rating for Boston Scientific (BSX)
• Positive Sentiment: Analyst write-ups (Zacks / Yahoo) highlight Boston Scientific’s history of beating estimates, suggesting the company has a reasonable chance to outpace consensus again when it reports — a potential near-term upside catalyst. Will Boston Scientific (BSX) Beat Estimates Again in Its Next Earnings Report?
• Positive Sentiment: Market commentary notes BSX shares rose Tuesday (though still underperforming the broader market), reflecting investor appetite into seasonally active medical devices names ahead of earnings. Boston Scientific Corp. stock rises Tuesday, still underperforms market
• Neutral Sentiment: Boston Scientific is expected to announce quarterly results on Wednesday; the report and management commentary will likely be the main near-term driver of volatility and direction. Boston Scientific (BSX) Expected to Announce Earnings on Wednesday
• Negative Sentiment: Multiple law firms have filed notices or solicited plaintiffs alleging securities fraud tied to disclosures between July 23, 2025 and Feb 3, 2026 (some claims reference alleged concealment of electrophysiology demand weakness). These class-action filings and the approaching May 4 lead?plaintiff deadline create legal and headline risk that could weigh on the stock. Representative notices: PR Newswire – Frank R. Cruz notice GlobeNewsWire – Pomerantz notice Newsfile – Rosen Law Firm notice

Insider Transactions at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 0.34% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. increased its stake in Boston Scientific by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock valued at $13,319,060,000 after purchasing an additional 1,436,550 shares in the last quarter. State Street Corp increased its stake in Boston Scientific by 1.4% during the 4th quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock valued at $6,278,422,000 after purchasing an additional 920,495 shares in the last quarter. Capital World Investors boosted its holdings in shares of Boston Scientific by 1.9% in the 4th quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock valued at $2,588,953,000 after acquiring an additional 502,627 shares during the last quarter. Norges Bank purchased a new stake in shares of Boston Scientific in the 4th quarter valued at $2,199,395,000. Finally, Morgan Stanley boosted its holdings in shares of Boston Scientific by 10.8% in the 4th quarter. Morgan Stanley now owns 22,960,556 shares of the medical equipment provider’s stock valued at $2,189,289,000 after acquiring an additional 2,246,308 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.